PL1923463T3 - Peptyd antygenowy do odrzucania raka pochodzący z glipikan-3 (GPC3) do zastosowania u HLA-A2-pozytywnego pacjenta i środek farmaceutyczny zawierający antygen - Google Patents

Peptyd antygenowy do odrzucania raka pochodzący z glipikan-3 (GPC3) do zastosowania u HLA-A2-pozytywnego pacjenta i środek farmaceutyczny zawierający antygen

Info

Publication number
PL1923463T3
PL1923463T3 PL06796310T PL06796310T PL1923463T3 PL 1923463 T3 PL1923463 T3 PL 1923463T3 PL 06796310 T PL06796310 T PL 06796310T PL 06796310 T PL06796310 T PL 06796310T PL 1923463 T3 PL1923463 T3 PL 1923463T3
Authority
PL
Poland
Prior art keywords
antigen
gpc3
glypican
hla
cancer
Prior art date
Application number
PL06796310T
Other languages
English (en)
Inventor
Yasuharu Nishimura
Tetsuya Nakatsura
Hiroyuki Komori
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of PL1923463T3 publication Critical patent/PL1923463T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL06796310T 2005-08-09 2006-08-08 Peptyd antygenowy do odrzucania raka pochodzący z glipikan-3 (GPC3) do zastosowania u HLA-A2-pozytywnego pacjenta i środek farmaceutyczny zawierający antygen PL1923463T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005230702 2005-08-09
PCT/JP2006/315631 WO2007018199A1 (ja) 2005-08-09 2006-08-08 HLA-A2陽性者用glypican-3(GPC3)由来癌拒絶抗原ペプチド及びこれを含む医薬
EP06796310A EP1923463B1 (en) 2005-08-09 2006-08-08 Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen

Publications (1)

Publication Number Publication Date
PL1923463T3 true PL1923463T3 (pl) 2012-02-29

Family

ID=37727382

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06796310T PL1923463T3 (pl) 2005-08-09 2006-08-08 Peptyd antygenowy do odrzucania raka pochodzący z glipikan-3 (GPC3) do zastosowania u HLA-A2-pozytywnego pacjenta i środek farmaceutyczny zawierający antygen

Country Status (13)

Country Link
US (2) US8053556B2 (pl)
EP (1) EP1923463B1 (pl)
JP (1) JP5299942B2 (pl)
KR (1) KR101304243B1 (pl)
CN (3) CN103242428B (pl)
AU (1) AU2006277295B2 (pl)
CA (1) CA2619443C (pl)
ES (1) ES2373055T3 (pl)
IL (1) IL189389A (pl)
PL (1) PL1923463T3 (pl)
PT (1) PT1923463E (pl)
RU (1) RU2395519C2 (pl)
WO (1) WO2007018199A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103242428B (zh) 2005-08-09 2015-04-15 肿瘤疗法.科学股份有限公司 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3 (gpc3)的癌症排斥抗原肽以及含有该肽的药物
RU2451521C2 (ru) 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
TWI615403B (zh) * 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
US20130217122A1 (en) * 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
EP3511425A1 (en) * 2012-07-12 2019-07-17 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
ES2844700T3 (es) * 2014-09-26 2021-07-22 Baylor College Medicine Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva
BR112017006969A2 (pt) 2014-10-07 2017-12-19 Cytlimic Inc peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
TW201636358A (zh) * 2014-12-09 2016-10-16 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｇｐｃ３抗原決定位胜肽及含此之疫苗
TW202115102A (zh) * 2015-03-09 2021-04-16 日商賽多利克公司 來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法
CN114262380A (zh) 2015-03-18 2022-04-01 欧姆尼赛特有限公司 包含经修饰的α病毒表面糖蛋白与肿瘤相关抗原的融合蛋白及其方法
ES2844049T3 (es) 2015-04-07 2021-07-21 Cytlimic Inc Adyuvante para vacunas contra el cáncer
US10273275B2 (en) * 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
BR112019006075A2 (pt) 2016-10-11 2019-06-18 Cytlimic Inc medicamento
JP2018093823A (ja) * 2016-12-15 2018-06-21 Ｈｅａｒｔｓｅｅｄ株式会社 未分化幹細胞除去剤及び未分化幹細胞除去方法
CN106822861A (zh) * 2017-01-12 2017-06-13 中国人民解放军第二军医大学 抗原肽gpc3‑1和gpc3‑3在制备治疗肝癌药物中的应用
WO2018143454A1 (ja) * 2017-02-06 2018-08-09 国立研究開発法人国立がん研究センター 新規ｔ細胞受容体
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CN108144071B (zh) * 2017-12-13 2021-05-18 中国医学科学院肿瘤医院 原发性肝癌磁共振双靶点特异性分子探针及其制备方法
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN119384291A (zh) * 2022-05-18 2025-01-28 国立研究开发法人国立癌症研究中心 利用通用癌抗原鸡尾酒的癌症疫苗、tcr/car-t细胞治疗药、伴随诊断方法和基于血中循环癌细胞检测的癌症发病风险诊断方法
WO2024227447A1 (en) * 2023-05-03 2024-11-07 Immunoracle Inc. Compositions and methods of analyzing a sample for antigen-specific immune cells
CN118909052B (zh) * 2024-09-23 2024-12-20 湖南中晟全肽生物科技股份有限公司 一种靶向gpc3的多肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US6326200B1 (en) * 1997-06-23 2001-12-04 Ludwig Institute For Cancer Research Isolated nona-and decapeptides which bind to HLA molecules, and the use thereof
WO1999037764A2 (en) * 1998-01-27 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie New members of the glypican gene family
AU2914501A (en) * 1999-12-28 2001-07-09 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
CN1280307C (zh) * 2001-04-03 2006-10-18 宝生物工程株式会社 细胞毒性t淋巴细胞
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
AU2003254950A1 (en) * 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
WO2004048938A2 (en) * 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US7303914B2 (en) * 2003-01-30 2007-12-04 Hongyang Wang Monoclonal antibody against human hepatoma and use thereof
JP4336898B2 (ja) 2003-10-29 2009-09-30 財団法人くまもとテクノ産業財団 悪性黒色腫（メラノーマ）の診断剤
WO2006043362A1 (ja) 2004-10-19 2006-04-27 Kumamoto University 悪性黒色腫（メラノーマ）の新規な診断キット
CN103242428B (zh) 2005-08-09 2015-04-15 肿瘤疗法.科学股份有限公司 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3 (gpc3)的癌症排斥抗原肽以及含有该肽的药物
RU2451521C2 (ru) 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их

Also Published As

Publication number Publication date
CA2619443C (en) 2014-07-08
IL189389A0 (en) 2008-06-05
JPWO2007018199A1 (ja) 2009-02-19
CN101313063B (zh) 2013-04-03
EP1923463A4 (en) 2009-09-09
CN103242428A (zh) 2013-08-14
BRPI0614590A2 (pt) 2013-05-14
PT1923463E (pt) 2011-11-24
KR20080056153A (ko) 2008-06-20
US8535942B2 (en) 2013-09-17
RU2008109015A (ru) 2009-09-20
CN103242428B (zh) 2015-04-15
IL189389A (en) 2011-11-30
CN104877008B (zh) 2018-06-05
ES2373055T3 (es) 2012-01-31
KR101304243B1 (ko) 2013-09-05
CN101313063A (zh) 2008-11-26
JP5299942B2 (ja) 2013-09-25
US8053556B2 (en) 2011-11-08
US20090239806A1 (en) 2009-09-24
EP1923463B1 (en) 2011-10-05
HK1118079A1 (en) 2009-01-30
CN104877008A (zh) 2015-09-02
US20120040452A1 (en) 2012-02-16
EP1923463A1 (en) 2008-05-21
WO2007018199A1 (ja) 2007-02-15
AU2006277295A1 (en) 2007-02-15
AU2006277295B2 (en) 2011-08-11
RU2395519C2 (ru) 2010-07-27
CA2619443A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
PL1923463T3 (pl) Peptyd antygenowy do odrzucania raka pochodzący z glipikan-3 (GPC3) do zastosowania u HLA-A2-pozytywnego pacjenta i środek farmaceutyczny zawierający antygen
IL261346A (en) Tissue protective peptides and their uses
EP1751179A4 (en) PEPTIDES DERIVED FROM THE CASEIN AND THEIR THERAPEUTIC USES
EP2102355A4 (en) PROTEINS AND PEPTIDES WITH EXTENDED ACTION AND METHODS OF PRODUCTION AND USE THEREOF
EG26619A (en) PEG-quadrangle arbor polymer for binding to proteins and peptides
IL184284A0 (en) Modified beta thymosin peptides
IL191152A0 (en) Polypeptide films and methods
PL2010572T3 (pl) Białka fuzyjne zawierające polipeptydy HPV i peptydy wzmagające odporność do leczenia i zapobiegania rakowi szyjki macicy
EP1976864A4 (en) NEW PEPTIDE AND ITS USE
IL188153A0 (en) Supravalent peptide compounds and processor for the preparation thereof
PL1890720T3 (pl) Kompozycje farmaceutyczne zawierające peptydy pochodzące z kazeiny i sposoby ich stosowania
EP1859063A4 (en) REPLIKIN PEPTIDES AND USES THEREOF
ZA200801874B (en) Antigenic peptides and their use
GB0427267D0 (en) Peptide adjuvants
EP1981704A4 (en) DEVICE AND METHODS FOR PREPARING SAMPLES OF PEPTIDES AND PROTEINS FROM A SOLUTION
GB0402129D0 (en) Therapeutic and diagnostic peptides
ZA200800566B (en) Therapeutic peptides and vaccines
GB0526120D0 (en) Therapeutic peptides
ZA200710374B (en) Pharmaceutical compositions comprising casein derived peptides and methods of use thereof
GB0521490D0 (en) RFamide-related peptide precursor proteins and RFamide peptides
GB0503093D0 (en) Ricin-binding peptide and methods for use thereof
GB0418156D0 (en) RFamide-related peptide precursor proteins and RFamide peptides
GB0425731D0 (en) Isolated peptides and uses thereof
IL222485A (en) Medical preparations that contain peptide-derived peptides and methods for their use
IL187120A0 (en) Pharmaceutical compositions comprising casein derived peptides and methods of use thereof